# Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers

**Authors:** Yuk-Kwan Chang, Wing-Pan Luk, Ling-Hiu Fung, Ava Kwong

PMC · DOI: 10.1007/s12282-026-01822-x · Breast Cancer (Tokyo, Japan) · 2026-02-03

## TL;DR

This study evaluates breast cancer surveillance in BRCA mutation carriers in Asia, showing early detection and low mortality despite low preventive surgery rates.

## Contribution

The study presents the first long-term Asian cohort data on BRCA surveillance outcomes, emphasizing structured screening effectiveness.

## Key findings

- Structured surveillance detected 64 breast cancers with an 89.1% early-stage diagnosis rate.
- Interval cancers were uncommon, and no breast cancer-specific deaths occurred among 26 newly diagnosed carriers.
- Overall breast cancer-specific mortality was 2.4%, with most deaths due to ovarian cancer.

## Abstract

Long-term outcome on breast cancer surveillance in BRCA mutation carriers are limited, especially in Asian populations where uptake of preventive surgery is low.

We conducted a retrospective cohort study of 722 female BRCA1 and BRCA2 mutation carriers enrolled between January 2007 and December 2024 in the Hong Kong Hereditary Breast Cancer Family Registry. Of these, 702 (97.2%) underwent structured high-risk surveillance comprising biannual clinical breast examination and alternating 6-monthly breast magnetic resonance imaging and mammography or digital breast tomosynthesis with ultrasonography. The outcomes were breast cancer detection rate, stage, nodal status, interval cancer occurrence, and breast cancer–specific mortality.

Risk-reducing mastectomy was undertaken by 90 out of 722 carriers (12.5%). Surveillance detected 64 breast cancers during 4,398 imaging sessions (detection rate 1.5%). Most cancers (89.1%) were diagnosed at stage 0 or I, and 95.3% were node- negative. Interval cancers were uncommon. Among 304 carriers initially free of breast cancer who later developed the disease (n = 26), no breast cancer–specific death occurred. Overall, breast cancer–specific mortality in the cohort was 2.4%, with most deaths due to ovarian cancer with a median follow-up of 39.1 months (range, 6-212.3). Longer term follow-up is warranted.

In this first Asian surveillance cohort of BRCA mutation carriers, prophylactic mastectomy uptake was low, yet structured screening enabled early-stage detection and minimal interval cancer. Surveillance should be considered as a key management strategy, with preventive surgery options individualized and cost-effectiveness evaluated.

## Linked entities

- **Genes:** BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675]
- **Diseases:** breast cancer (MONDO:0004989), ovarian cancer (MONDO:0005140)

## Full-text entities

- **Genes:** BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}
- **Diseases:** breast cancer (MESH:D001943)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960395/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960395/full.md

---
Source: https://tomesphere.com/paper/PMC12960395